Last reviewed · How we verify
NCT05389280
Impact of Acute Kidney Injury on Sarcopenia and Frailty in Patients With Liver Cirrhosis
trial in Cirrhosis in 80 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Kangbuk Samsung Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 23 March 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 March 2023 |
| Sites | 1 location across South Korea |
Conditions studied
- Cirrhosis — all drugs for Cirrhosis →
- Kidney Injury — all drugs for Kidney Injury →
- Sarcopenia — all drugs for Sarcopenia →
- Frailty — all drugs for Frailty →
Sponsor
Kangbuk Samsung Hospital
Who can join
20 and older, any sex, with Cirrhosis or Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this prospective observational study is to evaluate the impact of acute kidney injury on sarcopenia and frailty in patients with liver cirrhosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05389280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cirrhosis
Currently open trials in the same condition.
- NCT07322237 — DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis · Phase 4 · recruiting
- NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
- NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
- NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
- NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting
Other Kangbuk Samsung Hospital trials
Trials by the same sponsor.
- NCT07396961 — Consistency of ASIS Line vs. Tuffier's Line for Lumbar Level Identification · not yet recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT06773585 — Investigations of Factors Associated With Treatment Response and Prognosis in Anxiety Disorders · not yet recruiting
- NCT06130137 — Gut Microbiome in People Living With HIV and HBV · not yet recruiting
- NCT05538741 — Hypotension After Anesthetic Induction with Remimazolam in Elderly · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05389280 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kangbuk Samsung Hospital
- Last refreshed: 25 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05389280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing